Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Medchemexpress LLC MDL-29951 | 130798-51-5 | 99.2% | 302.11 | 5 MG
SDP

Catalog No. 502030711
Encompass_Preferred

MDL-29951 is a novel glycine antagonist of NMDA receptor activation, exhibiting a Ki of 0.14 μM for [3H]glycine binding both in vitro and in vivo. It is intended for research use only.

  • Approximately 2000-fold selective for the glycine binding site over glutamate recognition sites.
  • Inhibits human F16Bpase (IC50=2.5 μM), porcine kidney (IC50=1.0 μM), and rabbit liver (IC50=0.21 μM) isoforms of the enzyme.
  • Promotes Ca2+ signaling responses and inhibits cyclic adenosine monophosphate (cAMP) accumulation in rat oligodendrocyte precursor cells.
  • Exhibits GPCR-mediated signaling activities, including G protein-dependent activation of ERK1/2 and recruitment of β-arrestin.

Catalog No. 50-203-0711 Supplier Medchemexpress LLC Supplier No. HY163125MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

MDL-29951 is a novel glycine antagonist of NMDA receptor activation, exhibiting a Ki of 0.14 μM for [3H]glycine binding both in vitro and in vivo. It is intended for research use only.

  • Approximately 2000-fold selective for the glycine binding site over glutamate recognition sites.
  • Inhibits human F16Bpase (IC50=2.5 μM), porcine kidney (IC50=1.0 μM), and rabbit liver (IC50=0.21 μM) isoforms of the enzyme.
  • Promotes Ca2+ signaling responses and inhibits cyclic adenosine monophosphate (cAMP) accumulation in rat oligodendrocyte precursor cells.
  • Exhibits GPCR-mediated signaling activities, including G protein-dependent activation of ERK1/2 and recruitment of β-arrestin.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.